

MAR 17 1977

NIH Guide for Grants and Contracts
Vol. 6, No. 6, March 14, 1977

Page One

CANCER RESEARCH EMPHASIS GRANTS
(CREG)

A N N O U N C E M E N T

TITLE - REASONS FOR VARIATION IN CANCER PATIENT SURVIVAL BY RACE

SCIENTIFIC PROGRAM REQUIREMENT The National Cancer Institute (NCI) is accepting applications for support of research projects designed to increase knowledge concerning the basis for variation by race in cancer patient survival. For many forms of cancer, the survival experience for white patients is more favorable than that for black patients even when the disease is considered localized at diagnosis. Furthermore, a higher percentage of black patients than white have metastatic disease when cancer is first discovered.

Research in this area might include sociocultural parameters in an attempt to explain possible differences by race in delay from onset of disease to cancer diagnosis. Studies of recurrence and/or patient survival must take into account variables of known prognostic and etiologic significance, e.g. histologic type, extent of disease, and other demographic, morphologic, and physiological descriptions of neoplasm and host. Proposals should be oriented toward specific forms of cancer and should include detailed plans for data collection and statistical analysis.

SIGNIFICANCE TO NCI PROGRAM GOALS Recognition of cancer at its most limited and early manifestation is considered a promising way of reducing cancer mortality. Therefore, study of groups of patients demonstrating differences in survival improves the chances of identifying biological factors that may prove useful in the selection of optimum therapeutic approaches, or in modifying some aspects of the delivery of, or access to, medical care.

APPLICATION REQUIREMENTS

1. *ELIGIBILITY* All nonprofit organizations and institutions, State and local governments and their agencies, authorized Federal institutions, and individuals are eligible, according to NIH grants policies.
2. *THE APPLICATION* Applicants should propose individual projects. The application should very specifically describe the background for the proposed project, the rationale behind conducting the proposed study, measurable objectives, and significance in advancing knowledge of cancer etiology and prognosis. Applicants must complete portions of the application pertaining to procedural details including study design, assurance of high quality data and analytical procedures, the investigator's related experience, facilities available, budget, and biographical information for key professional personnel. The application should also state the duration of time for which the support is requested. It is anticipated that the project period will not exceed five years.

Page Two

3. SUBMISSION Use application form PHS 398. In both the covering letter and at the top of the space provided for an abstract on page 2 of the application, identify this CREG announcement by its title and the number DCCP-32 and its date of publication. Mail the application and letter to Division of Research Grants, National Institutes of Health, Bethesda, Maryland 20014.

4. RECEIPT DATE Applications must be received in the Division of Research Grants, NIH, no later than November 1, 1977, in order to be considered in the competition under this announcement.

REVIEW

Upon receipt, applications will be reviewed by the Division of Research Grants (DRG) and NCI staff for responsiveness to this announcement. If an application is judged unresponsive, the applicant will be given an opportunity to withdraw the application or to submit it for consideration in the traditional grant programs of NIH. Applications judged responsive will be reviewed initially for scientific merit by DRG study sections in February/March 1978, and secondly by the National Cancer Advisory Board in May 1978.

DRG will not accept an application in response to a CREG announcement that is identical to one concurrently being considered by NCI or other NIH awarding units.

For further information potential applicants may contact Dr. James L. Murray, Biometry Branch, Division of Cancer Cause and Prevention, National Cancer Institute, Room C-505, Landow Building, Bethesda, Maryland 20014; telephone, (301) 496-3116.

CANCER RESEARCH EMPHASIS GRANTS
(CREG)

A N N O U N C E M E N T

TITLE - *CANCER EPIDEMIOLOGY IN COLLABORATION WITH THE
NCI PROGRAM OF CANCER SURVEILLANCE,
EPIDEMIOLOGY, AND END RESULTS (SEER)*

SCIENTIFIC PROGRAM REQUIREMENT The National Cancer Institute (NCI) is accepting applications for support of research projects in the field of cancer epidemiology and etiology which will be conducted in collaboration with cancer registries participating in the SEER program of cancer Surveillance, Epidemiology, and End Results. The SEER program provides information on trends in the incidence of the various forms of cancer, variation in the occurrence of cancer among different population groups and in different geographic areas, changes, in general treatment practice, and the associated cancer patient survival patterns. Data are obtained from a selected number of population-based cancer registries that provide uniform information on a continuing basis and participate in ad hoc studies designed to identify and assess etiologic and prognostic factors.

Only limited pilot or feasibility studies can be supported under the present contract agreements with the participating registries. Therefore, NCI is now soliciting full-scale comprehensive CREG research proposals for analytic studies in etiology and/or prognosis for any form of cancer. Of special interest are research projects which may lead to identification of factors which can be modified to reduce the incidence and mortality of cancer. Purely descriptive studies are not desired. Although specific research protocols are requested, the actual approaches and methods will be left to the initiative of the applicants. Studies may be either retrospective or prospective in design.

Registries currently participating in the SEER program are:

<u>Registry Institution</u>	<u>Area Covered</u>	<u>Population Covered - 1970</u>
1. California State Department of Health	San Francisco Bay area, five counties	3,109,519
2. Charity Hospital of Louisiana at New Orleans	New Orleans area, three parishes	982,224
3. Connecticut State Department of Health	Entire State of Connecticut	3,031,709
4. Emory University	Atlanta, five county Metropolitan area	1,455,100
5. Fred Hutchinson Cancer Research Center	Seattle-Tacoma area, thirteen counties	2,300,000
6. Research Corporation of the University of Hawaii	Entire State of Hawaii	768,561

<u>Registry Institution</u>	<u>Area Covered</u>	<u>Population Covered - 1970</u>
7. University of Iowa	Entire State of Iowa	2,824,376
8. Michigan Cancer Foundation	Detroit Metropolitan area, three counties	4,199,931
9. University of New Mexico	Entire State of New Mexico	1,016,000
10. Commonwealth of Puerto Rico	Entire island of Puerto Rico	2,712,000
11. University of Utah	Entire State of Utah	1,059,273
TOTAL population covered, present participants		23,458,693

SIGNIFICANCE TO NCI PROGRAM GOALS The SEER program contributes to Objective No. 5 of the National Cancer Plan, i.e., "develop the means to achieve an accurate assessment of the presence, extent, and probable cause of cancer risks in population groups (including attention to precancerous lesions) and of individuals alone (diagnosis) and in groups (detection) as an aid to prevention, cure, or prognosis." The program also provides a means for measuring progress in achieving Objective No. 6, namely, "develop the means to cure as many patients as possible and to maintain maximum control of the precancerous process in patients not cured."

It is anticipated that epidemiologic research supported by this CREG program will produce significant new information which will help achieve the objectives of the National Cancer Plan.

APPLICATION REQUIREMENTS

1. *ELIGIBILITY* All nonprofit organizations and institutions, State and local governments and their agencies, authorized Federal institutions, and individuals are eligible, according to NIH grants policies, regardless of whether or not they are participating in the SEER program.
2. *THE APPLICATION* Applicants should propose individual projects. The application should very specifically describe the background for the proposed project, the rationale behind conducting the proposed study, measurable objectives, and significance in advancing knowledge of cancer etiology and prognosis. Applicants must complete portions of the application pertaining to procedural details including study design, assurance of high quality data and analytical procedures, the investigator's related experience, facilities available, budget, and biographical information for key professional personnel. Applicants are expected to make their own arrangements for collaboration with any of the participating SEER registries, and a letter of support should be included in the grant application. The application should also state the duration of time for which the support is requested. It is anticipated that the project period will not exceed five years.

3. SUBMISSION Use application form PHS 398. In both the covering letter and at the top of the space provided for an abstract on page 2 of the applications, identify this CREG announcement by its title and the number DCCP-33 and its date of publication. Mail the application and letter to Division of Research Grants, National Institutes of Health, Bethesda, Maryland 20014.
4. RECEIPT DATE Applications must be received in the Division of Research Grants, NIH, no later than November 1, 1977, in order to be considered in the competition under this announcement.

REVIEW

Upon receipt, applications will be reviewed by the Division of Research Grants (DRG) and NCI staff for responsiveness to this announcement. If an application is judged unresponsive, the applicant will be given an opportunity to withdraw the application or to submit it for consideration in the traditional grant programs of NIH. Applications judged responsive will be reviewed initially for scientific merit by DRG study sections in February/March 1978, and secondly by the National Cancer Advisory Board in May 1978.

DRG will not accept an application in response to a CREG announcement that is identical to one concurrently being considered by NCI or other NIH awarding units.

For further information potential applicants may contact Dr. James L. Murray, Biometry Branch, Division of Cancer Cause and Prevention, National Cancer Institute, Room C-505, Landow Building, Bethesda, Maryland 20014; telephone, (301) 496-3116.